The race to be the first to make a coronavirus vaccine is over, but that doesn't mean the competition has ended. Its candidate, INO-4800, will only start its phase 3 clinical trials sometime this summer. If Inovio's jab doesn't cut the mustard, it might not even get approved.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting